Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis

Journal of Clinical Microbiology

Volumn 41, Issue 9, 2003, Pages 4009-4015

  Miller, Melissa B ^a   Gilligan, Peter H ^a,b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEFOPERAZONE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ALCALIGENES; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASPERGILLUS; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BURKHOLDERIA CEPACIA; CHRONIC LUNG DISEASE; CYSTIC FIBROSIS; EPIDEMIOLOGICAL DATA; HAEMOPHILUS INFLUENZAE TYPE A; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

BACTERIAL INFECTIONS; BURKHOLDERIA INFECTIONS; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

ALCALIGENES; ASPERGILLUS; BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA CEPACIA; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE SEROTYPE A; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS; STENOTROPHOMONAS MALTOPHILIA;

EID: 0042922372     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.9.4009-4015.2003     Document Type: Short Survey

References (41)

1. Aaron, S. D., W. Ferris, K. Ramotar, K. Vandemheen, F. Chan, and R. Saginur. 2002. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J. Clin. Microbiol. 40:4172-4179.
2. Aris, R. M., J. C. Routh, J. J. LiPuma, D. G. Heath, and P. H. Gilligan. 2001. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am. J. Respir. Crit. Care Med. 164:2102-2106.
3. Arpi, M., M. A. Victor, I. Mortensen, A. Gottschau, and B. Bruun. 1996. In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods. APMIS 104:108-114.
4. Burns, J. L., R. L. Gibson, S. McNamara, D. Yim, J. Emerson, M. Rosenfeld, P. Hiatt, K. McCoy, R. Castile, A. L. Smith, and B. W. Ramsey. 2001. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 183:444-452.
5. Burns, J. L., L. Saiman, S. Whittier, J. Krzewinski, Z. Liu, D. Larone, S. A. Marshall, and R. N. Jones. 2001. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn. Microbiol. Infect. Dis. 39:257-260.
6. Burns, J. L., L. Saiman, S. Whittier, D. Larone, J. Krzewinski, Z. Liu, S. A. Marshall, and R. N. Jones. 2000. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeniginosa isolates from cystic fibrosis patients. J. Clin. Microbiol. 38:1818-1822.
7. Burns, J. L., J. M. Van Dalfsen, R. M. Shawar, K. L. Otto, R. L. Garber, J. M. Quan, A. B. Montgomery, G. M. Albers, B. W. Ramsey, and A. L. Smith. 1999. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179:1190-1196.
8. Chaparro, C., J. Maurer, C. Gutierrez, M. Krajden, C. Chan, T. Winton, S. Keshavjee, M. Scavuzzo, E. Tullis, M. Hutcheon, and S. Kesten. 2001. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am. J. Respir. Crit. Care Med. 163:43-48.
9. Chen, J. S., K. A. Witzmann, T. Spilker, R. J. Fink, and J. J. LiPuma. 2001. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J. Pediatr. 139:643-649.
10. Cystic Fibrosis Foundation. 1998. Patient registry 1997 annual report. Cystic Fibrosis Foundation, Washington, D.C.
11. Cystic Fibrosis Foundation. 2002. Patient registry 2001 annual report. Cystic Fibrosis Foundation, Washington, D.C.
12. Drevinek, P., H. Hrbackova, O. Cinek, J. Bartosova, O. Nyc, A. Nemec, and P. Pohunek. 2002. Direct PCR detection of Burkholderia cepacia complex and identification of its genomovars by using sputum as source of DNA. J. Clin. Microbiol. 40:3485-3488.
13. Frederiksen, B., C. Koch, and N. Hoiby. 1997. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23:330-335.
14. Gilligan, P. H. 1991. Microbiology of airway disease in patients with cystic fibrosis. Clin. Microbiol. Rev. 4:35-51.
15. Gilligan, P. H., P. A. Gage, D. F. Welch, M. J. Muszynski, and K. R. Wait. 1987. Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis. J. Clin. Microbiol. 25:1258-1261.
16. Givney, R., A. Vickery, A. Holliday, M. Pegler, and R. Benn. 1997. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J. Hosp. Infect. 35:27-36.
17. Graff, G. R., and J. L. Burns. 2002. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 121:1754-1760.
18. Heath, D. G., K. Hohneker, C. Carriker, K. Smith, J. Routh, J. J. LiPuma, R. M. Aris, D. Weber, and P. H. Gilligan. 2002. Six-year molecular analysis of Burkholderia cepacia complex isolates among cystic fibrosis patients at a referral center for lung transplantation. J. Clin. Microbiol. 40:1188-1193.
19. Henry, D., M. Campbell, C. McGimpsey, A. Clarke, L. Louden, J. L. Burns, M. H. Roe, P. Vandamme, and D. Speert. 1999. Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis. J. Clin. Microbiol. 37:1004-1007.
20. Hiatt, P. W., S. C. Grace, C. A. Kozinetz, S. H. Raboudi, D. G. Treece, L. H. Taber, and P. A. Piedra. 1999. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 103:619-626.
21. Isles, A., I. Maclusky, M. Corey, R. Gold, C. Prober, P. Fleming, and H. Levison. 1984. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 104:206-210.
22. Kahl, B., M. Herrmann, A. S. Everding, H. G. Koch, K. Becker, E. Harms, R. A. Proctor, and G. Peters. 1998. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J. Infect. Dis. 177:1023-1029.
23. Kilby, J. M., P. H. Gilligan, J. R. Yankaskas, W. E. Highsmith, Jr., L. J. Edwards, and M. R. Knowles. 1992. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 102:70-75.
24. Knowles, M. R., P. H. Gilligan, and R. C. Boucher. 2000. Cystic fibrosis, p. 767-772. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practices of infectious diseases, 5th ed. Churchill Livingstone, New York, N.Y.
25. Krueger, T. S., E. A. Clark, and D. E. Nix. 2001. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn. Microbiol. Infect. Dis. 41:71-78.
26. Lyczak, J. B., C. L. Cannon, and G. B. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222.
27. McDowell, A., E. Mahenthiralingam, J. E. Moore, K. E. Dunbar, A. K. Webb, M. E. Dodd, S. L. Martin, B. C. Millar, C. J. Scott, M. Crowe, and J. S. Elborn. 2001. PCR-based detection and identification of Burkholderia cepacia complex pathogens in sputum from cystic fibrosis patients. J. Clin. Microbiol. 39:4247-4255.
28. McMenamin, J. D., T. M. Zaccone, T. Coenye, P. Vandamme, and J. J. LiPuma. 2000. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest 117:1661-1665.
29. Morlin, G. L., D. L. Hedges, A. L. Smith, and J. L. Burns. 1994. Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa. J. Clin. Microbiol. 32:1027-1030.
30. Olivier, K. N., D. J. Weber, J. H. Lee, A. Handler, G. Tudor, P. L. Molina, J. Tomashefski, and M. R. Knowles. 2003. Nontuberculous mycobacteria. II. Nested-cohort study of impact on cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med. 167:835-840.
31. Saiman, L., J. L. Burns, D. Larone, Y. Chen, E. Garber, and S. Whittier. 2003. Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J. Clin. Microbiol. 41:492-494.
32. Saiman, L., Y. Chen, S. Tabibi, P. San Gabriel, J. Zhou, Z. Liu, L. Lai, and S. Whittier. 2001. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J. Clin. Microbiol. 39:3942-3945.
33. Saiman, L., D. Schidlow, and A. Smith (ed.). 1994. Concepts in care: microbiology and infectious disease in cystic fibrosis, vol. V. Cystic Fibrosis Foundation, Washington, D.C.
34. Shreve, M. R., S. Butler, H. J. Kaplowitz, H. R. Rabin, D. Stokes, M. Light, and W. E. Regelmann. 1999. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J. Clin. Microbiol. 37:753-757.
35. + Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat. Med. 1:661-666.
36. Tablan, O. C., T. L. Chorba, D. V. Schidlow, J. W. White, K. A. Hardy, P. H. Gilligan, W. M. Morgan, L. A. Carson, W. J. Martone, J. M. Jason, and W. R. Jarvis. 1985. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J. Pediatr. 107:382-387.
37. Thomas, S. R., A. Ray, M. E. Hodson, and T. L. Pitt. 2000. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax 55:795-797.
38. Vandamme, P., B. Holmes, T. Coenye, J. Goris, E. Mahenthiralingam, J. J. LiPuma, and J. R. Govan. 2003. Burkholderia cenocepacia sp. nov. - a new twist to an old story. Res. Microbiol. 154:91-96.
39. Whittier, S., R. L. Hopfer, M. R. Knowles, and P. H. Gilligan. 1993. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J. Clin. Microbiol. 31:861-864.
40. Wong, K., M. C. Roberts, L. Owens, M. Fife, and A. L. Smith. 1984. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J. Med. Microbiol. 17:113-119.
41. Worlitzsch, D., R. Tarran, M. Ulrich, U. Schwab, A. Cekici, K. C. Meyer, P. Birrer, G. Bellon, J. Berger, T. Weiss, K. Botzenhart, J. R. Yankaskas, S. Randell, R. C. Boucher, and G. Doring. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Investig. 109:317-325.